In laboratories at India's CSIR-Central Food Technological Research Institute, scientists have isolated a protein that does what modern medicine has long struggled to achieve: it kills a dangerous pathogen while leaving the body's beneficial microbial community intact. The protein, SalE1a, targets drug-resistant Salmonella strains through a mechanism distinct from conventional antibiotics, arriving at a moment when the misuse of antimicrobials in agriculture has rendered many standard treatments ineffective. It is, at its core, a story about precision — the difference between a scalpel and a f
Scientists discover protein that kills Salmonella while sparing beneficial gut bacteria
A protein that kills the pathogen but spares the friend
Mark
So they found a protein that kills Salmonella. Why is that different from just using an antibiotic?
Mimi
Because this protein only kills Salmonella and leaves your good gut bacteria alone. Most antibiotics wipe out everything.
Luke
Do we know that for certain? The study tested it in the lab against friendly bacteria in a dish. That's not the same as what happens inside a human gut.
Mimi
Fair point. But the selectivity they're showing is real—it's not killing E. coli or other common gut residents in their tests.
Mark
And the resistance problem—how does this protein avoid the same fate as antibiotics?
Mimi
It works by a different mechanism. Instead of targeting a specific enzyme or pathway, it physically disrupts the bacterial membrane. That's harder for bacteria to evolve resistance to quickly.
Luke
Harder, but not impossible. Bacteria have been evolving defenses against bacteriocins for millions of years.
Mark
So what's the actual next step? Is this going into human trials?
Mimi
Not yet. They've shown it works in culture. Now they need to test whether it survives in the stomach, whether it reaches the intestines, whether the body tolerates it.
Luke
And they need to figure out how to manufacture it at scale and at a price that makes sense for a therapeutic.
Mark
But the core finding—that you can make a protein that's selective—that's solid?
Mimi
Yes. That's the discovery. Whether it becomes a medicine is a different question.
El Pulso
- Multidrug-resistant Salmonella, fueled by decades of antibiotic overuse in farming and meat processing, is outpacing the drugs designed to stop it.
- Conventional antibiotics strike indiscriminately, wiping out the gut's beneficial bacteria alongside pathogens and leaving patients vulnerable to cascading health disruptions.
- SalE1a disrupts Salmonella's cell membranes and floods bacterial cells with reactive oxygen species — a dual assault that kills the pathogen without touching friendly gut microbes.
- The protein held its killing power across varying pH levels, salt concentrations, and metal ion environments, suggesting it could survive the harsh chemistry of the human digestive tract.
- Proof of concept is established in the lab, but questions of safe delivery, bodily stability, and scalable manufacturing still stand between this discovery and a viable treatment.
In laboratories at India's CSIR-Central Food Technological Research Institute, scientists have isolated a protein that does what modern medicine has long struggled to achieve: it kills a dangerous pathogen while leaving the body's beneficial microbial community intact. The protein, SalE1a, targets drug-resistant Salmonella strains through a mechanism distinct from conventional antibiotics, arriving at a moment when the misuse of antimicrobials in agriculture has rendered many standard treatments ineffective. It is, at its core, a story about precision — the difference between a scalpel and a flood — and what becomes possible when science learns to make that distinction.
Scientists at India's CSIR-Central Food Technological Research Institute have isolated a bacterial protein called SalE1a that kills Salmonella while leaving beneficial gut bacteria unharmed — a distinction that carries enormous weight as antibiotic resistance tightens its hold on foodborne illness.
SalE1a belongs to a class of naturally occurring compounds called bacteriocins, which bacteria produce to compete with rivals. Researchers Kammara Rajagopal, Anagha Kalathil, and their team engineered E. coli to manufacture the protein, yielding roughly 2.8 milligrams per liter of culture. The logic is elegant: recruit one microorganism to produce a weapon against another.
What sets SalE1a apart is its selectivity. It demonstrated strong killing power against multiple Salmonella strains while leaving the digestive tract's microbial ecosystem entirely intact — a sharp contrast to broad-spectrum antibiotics, which obliterate beneficial and harmful bacteria alike. The protein works by destabilizing pathogenic cell membranes and generating reactive oxygen species that damage bacterial machinery from within. Crucially, it retained this potency across a wide range of pH levels and chemical conditions, suggesting it could remain functional inside the human gut.
The discovery arrives against a backdrop of crisis. Routine antibiotic use in agriculture has accelerated the evolution of resistant Salmonella strains, and when those strains reach humans through contaminated food, conventional treatments increasingly fail. A protein that bypasses accumulated resistance through an entirely different mechanism represents a genuinely new kind of tool.
The laboratory proof of concept is solid. Whether SalE1a can be safely delivered to infection sites, remain stable long enough to act, and be manufactured at practical scale are questions that remain open — but the foundational insight stands: it is possible to build something that tells the difference between a threat and a friend.
Researchers at India's CSIR-Central Food Technological Research Institute have isolated a bacterial protein that kills Salmonella without harming the beneficial microbes living in the human gut—a distinction that matters enormously in an era when antibiotics are losing their grip on foodborne pathogens.
The protein, called SalE1a, belongs to a family of naturally occurring antimicrobial compounds known as bacteriocins, which bacteria produce to fight off competitors. Kammara Rajagopal, Anagha Kalathil, and their team engineered the protein by inserting the SalE1a gene into laboratory strains of E. coli, which then manufactured the compound at a yield of approximately 2.8 milligrams per liter of culture. The approach is straightforward in principle: use one microorganism to manufacture a weapon against another.
What makes SalE1a noteworthy is its selectivity. In testing, the protein demonstrated strong killing power against multiple Salmonella serovars—the different strains that cause food poisoning in humans—while leaving the friendly bacteria that colonize the digestive tract completely unscathed. This precision is not trivial. Most broad-spectrum antibiotics obliterate both pathogens and beneficial microbes indiscriminately, disrupting the microbial ecosystem that supports digestion, immune function, and metabolic health. A therapeutic agent that can eliminate a specific threat without collateral damage represents a fundamentally different class of tool.
The mechanism is elegant. SalE1a kills by destabilizing the bacterial cell membrane, disrupting the electrical gradient that pathogenic bacteria depend on to survive. The protein also generates reactive oxygen species—chemically reactive molecules that damage cellular machinery from within. The researchers found that SalE1a retained its killing power across a wide range of pH conditions and in the presence of various salts and metal ions, suggesting the protein would remain functional in the acidic environment of the stomach and the chemically complex setting of the small intestine.
The timing of this discovery reflects a pressing public health crisis. Multidrug-resistant Salmonella strains have proliferated in recent decades, driven largely by the routine use of antibiotics in agriculture and meat processing—a practice that accelerates the evolution of resistance by exposing bacteria to drugs they learn to survive. When these resistant strains reach human populations through contaminated food, conventional antibiotics often fail. A protein like SalE1a, which works through a different mechanism and targets a specific pathogen, could bypass resistance that has accumulated against traditional drugs.
The researchers have demonstrated proof of concept in the laboratory. Whether SalE1a can translate into a practical therapeutic—whether it can be delivered safely to the site of infection, whether it will remain stable in the body long enough to work, whether it can be manufactured at scale and cost—remains to be determined. But the fundamental discovery is solid: a protein exists that can distinguish between a pathogen and a friend, and kill one while sparing the other.
Citas Notables
The protein offers a tool to curb the rise of multidrug-resistant Salmonella strains caused by antibiotic misuse in agriculture and meat processing— CSIR-Central Food Technological Research Institute research team
Quieres la nota completa?
Lee el original en Nature ↗
Science & Space